3 results
Primary:• To compare the overall survival (OS) of patients in the rigosertib group vs the Physician*s Choice group, in all patients and in a subgroup of patients with IPSS-R very high riskSecondary efficacy• To compare rigosertib to Physician*s…
In this study, we will investigate how quickly and to what extent CKD 506 is absorbed, transported, and eliminated from the body. In addition, we will evaluate a possible interaction between CKD 506 and midazolam. We will do this by investigating…
Primary To confirm superiority on body weight reduction of CagriSema 2.4 mg/2.4 mg versus placebo as adjuncts to reduced-calorie diet andincreased physical activity in participants with overweight or obesity. Secondary To confirm superiority of…